Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
35 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
129.9 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
51
51 articles ont été cités au moins 51fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
23 775
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
252
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
121
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut de Cancérologie de l'Ouest · Centre Hospitalier René-Dubos
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
2026ArticleEuropean Urology
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12
2026ArticleEuropean Journal of Cancer
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
2025CongrèsAmerican Society of Clinical Oncology (ASCO) Annual meeting 2025
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
2024ArticleEuropean Journal of Cancer
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
2024ArticleEuropean Journal of Cancer
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials
2024ArticleEuropean Urology Oncology
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial
2024ArticleThe Lancet. Healthy longevity
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
2024ArticleLancet Oncology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
ICO - SITE GAUDUCHEAU
CENTRE RENE GAUDUCHEAU BD JACQUES MONOD, 44805 ST HERBLAIN CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The New England journal of medicine · 2021
The New England journal of medicine · 2018
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
PURPOSE Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these patients were excluded from pivotal studies. We aimed to assess the activity of nivolumab in this population. METHODS The GETUG-AFU 26 NIVOREN phase II trial assessed the activity and safety of nivolumab in patients with metastatic ccRCC who failed vascular endothelial growth factor–directed therapies ( ClinicalTrials.gov identifier: NCT03013335 ). Patients with asymptomatic brain metastases were prospectively identified and underwent dedicated brain evaluation. Two cohorts were constituted: cohort A comprised patients with previously untreated brain metastases, and cohort B comprised patients whose brain metastases underwent prior therapy. The primary end point was intracranial response rate in cohort A. RESULTS Seventy-three patients with brain metastases were included: 39 in cohort A and 34 in cohort B. Intracranial response rate was 12% in cohort A; no objective response was reported in patients with brain lesions that were multiple or larger than 1 cm. Median intracranial progression-free survival was 2.7 months (95% CI, 2.3 to 4.6 months) in cohort A and 4.8 months (95% CI, 3.0 to 8.0 months) in cohort B, with adjusted hazard ratio of 2.04 (95% CI, 1.08 to 3.83). Overall survival rate at 12 months was 67% (95% CI, 49.6% to 79.1%) in cohort A and 59% (95% CI, 40.6% to 73.2%) in cohort B. Most patients in cohort A (72%) needed subsequent focal brain therapy. Nivolumab was well tolerated, with no unexpected toxicity. CONCLUSION Nivolumab activity is limited in patients with untreated brain metastases from ccRCC. Brain imaging and focal therapy should be considered before immune checkpoint inhibitors in patients with metastatic ccRCC.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Clinical Trial, Phase III
Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Blay JY, Penel N, Toulmonde M, Valentin T, et al.
Scientific reports · 2023 · Randomized Controlled Trial
Marret G, Temam S, Kamal M, Even C, et al.
BMJ oncology · 2023 · Journal Article
Fayette J, Even C, Digue L, Geoffrois L, et al.
European urology oncology · 2023 · Randomized Controlled Trial
Grünwald V, Powles T, Kopyltsov E, Kozlov V, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Clinical Trial, Phase II
Thibault C, Fléchon A, Albiges L, Joly C, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Randomized Controlled Trial
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Randomized Controlled Trial
Racadot S, Thennevet I, Ouldbey Y, Kaminsky MC, et al.
Clinical genitourinary cancer · 2022 · Clinical Trial, Phase II
Rassy E, Dalban C, Colomba E, Derosa L, et al.
Clinical genitourinary cancer · 2021 · Clinical Trial, Phase III
Culine S, Harter V, Gravis G, Fléchon A, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Clinical Trial, Phase III
Tao Y, Aupérin A, Sun X, Sire C, et al.
The Lancet. Oncology · 2020 · Clinical Trial, Phase II
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Clinical Trial, Phase II
Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, et al.
European journal of cancer (Oxford, England : 1990) · 2019 · Clinical Trial, Phase II
Forster MD, Dillon MT, Kocsis J, Remenár É, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · Clinical Trial, Phase II
Flippot R, Dalban C, Laguerre B, Borchiellini D, et al.
JAMA oncology · 2019 · Clinical Trial, Phase III
Oudard S, Latorzeff I, Caty A, Miglianico L, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018 · Journal Article
Geoffrois L, Martin L, De Raucourt D, Sun XS, et al.
European urology oncology · 2024 · Journal Article
Billon E, Dalban C, Oudard S, Chevreau C, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Naffrichoux J, Poupin P, Pouillot W, Linassier C, et al.
The lancet. Healthy longevity · 2024 · Journal Article
Guigay J, Le Caer H, Ferrand FR, Geoffrois L, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, et al.
Clinical genitourinary cancer · 2022 · Clinical Trial, Phase II
Rassy E, Dalban C, Colomba E, Derosa L, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Clinical Trial, Phase III
European urology · 2025 · Journal Article
Flippot R, Vano YA, Dalban C, Beuselinck B, et al.
Nature medicine · 2021 · Clinical Trial, Phase I
Powles T, Carroll D, Chowdhury S, Gravis G, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Mourey L, Rainho LT, Dalban C, Carril-Ajuria L, et al.
Journal of clinical medicine · 2023 · Journal Article
Gluszak C, Campion L, Seegers V, Cojocarasu O, et al.
Clinical genitourinary cancer · 2021 · Journal Article
Culine S, Fléchon A, Gravis G, Roubaud G, et al.
Clinical genitourinary cancer · 2023 · Randomized Controlled Trial
Orlando V, Drubay D, Lavaud P, Faivre L, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Clinical Trial, Phase II
Borcoman E, Lalanne A, Delord JP, Cassier PA, et al.
Investigational new drugs · 2021 · Clinical Trial, Phase I
Marret G, Isambert N, Rezai K, Gal J, et al.
European journal of cancer (Oxford, England : 1990) · 2021 · Journal Article
Cancel M, Fromont G, Blonz C, Chevreau C, et al.
European urology · 2021 · Clinical Trial, Phase II
Courcier J, Dalban C, Laguerre B, Ladoire S, et al.
The New England journal of medicine · 2021 · Clinical Trial, Phase III
Motzer R, Alekseev B, Rha SY, Porta C, et al.
The New England journal of medicine · 2018 · Clinical Trial, Phase III
Méjean A, Ravaud A, Thezenas S, Colas S, et al.
European urology · 2018 · Clinical Trial, Phase III
Lavaud P, Gravis G, Foulon S, Joly F, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018 · Journal Article
Escudier B, Powles T, Motzer RJ, Olencki T, et al.
Tao Y, Aupérin A, Sun X, Sire C, et al.
Oral oncology · 2019 · Clinical Trial, Phase III
Haddad R, Guigay J, Keilholz U, Clement PM, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019 · Clinical Trial, Phase II
Flippot R, Dalban C, Laguerre B, Borchiellini D, et al.